Arcellx (NASDAQ:ACLX) Sees Strong Trading Volume – What’s Next?

Arcellx, Inc. (NASDAQ:ACLX) shares saw unusually-high trading volume on Tuesday . Approximately 4,739,269 shares traded hands during trading, an increase of 158% from the previous session’s volume of 1,833,981 shares.The stock last traded at $113.7530 and had previously closed at $113.75.

Arcellx News Roundup

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Shares have recently surged toward their 52‑week high, keeping momentum and investor interest alive despite the downgrades. Is It Too Late To Consider Arcellx (ACLX) After Its Recent Share Price Surge?
• Positive Sentiment: HC Wainwright issued an FY2030 earnings forecast for Arcellx, which keeps sell‑side coverage active and may support forward expectations; coverage/forecasts can sustain investor interest. FY2030 Earnings Forecast for Arcellx Issued By HC Wainwright
• Neutral Sentiment: Reported short‑interest data in filings appears anomalous/erroneous (shows zero with NaN changes and a 0.0 days‑to‑cover figure), so short‑squeeze risk is unclear from that report. (Data reliability issue.)
• Negative Sentiment: UBS cut its rating on Arcellx, adding to today’s negative analyst actions that can pressure sentiment. UBS downgrades Arcellx (ACLX)
• Negative Sentiment: Citigroup also downgraded the stock, contributing to a cluster of downgrades from major firms. Citigroup downgrades Arcellx (ACLX)
• Negative Sentiment: Several other brokerages have moved to “hold” (Leerink Partners, Evercore, Needham, Wells Fargo, Canaccord Genuity, Robert W. Baird), signaling reduced near‑term enthusiasm from sell‑side analysts and increasing downside risk if momentum fades. Arcellx (NASDAQ:ACLX) Cut to “Hold” at Robert W. Baird

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on ACLX shares. HC Wainwright cut shares of Arcellx from a “buy” rating to a “neutral” rating and set a $115.00 price objective on the stock. in a research report on Monday. Guggenheim downgraded Arcellx from a “buy” rating to a “neutral” rating and lowered their price target for the company from $120.00 to $115.00 in a report on Wednesday. Rothschild & Co Redburn lowered Arcellx from a “buy” rating to a “neutral” rating and set a $82.00 price target on the stock. in a research report on Thursday, February 12th. Citigroup downgraded Arcellx from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $110.00 to $115.00 in a research note on Tuesday. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $115.00 target price (up from $106.00) on shares of Arcellx in a research note on Monday. One equities research analyst has rated the stock with a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $111.87.

Arcellx Trading Up 0.1%

The firm has a market capitalization of $6.59 billion, a price-to-earnings ratio of -28.99 and a beta of 0.36. The company has a fifty day moving average price of $69.82 and a 200-day moving average price of $75.65.

Insider Transactions at Arcellx

In related news, insider Christopher Heery sold 7,437 shares of Arcellx stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $65.51, for a total value of $487,197.87. Following the transaction, the insider owned 29,631 shares in the company, valued at $1,941,126.81. This trade represents a 20.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last quarter, insiders have sold 19,450 shares of company stock valued at $1,283,477. Company insiders own 8.35% of the company’s stock.

Institutional Trading of Arcellx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACLX. MAI Capital Management acquired a new position in shares of Arcellx during the third quarter worth approximately $26,000. CWM LLC grew its position in Arcellx by 267.0% in the 3rd quarter. CWM LLC now owns 345 shares of the company’s stock worth $28,000 after purchasing an additional 251 shares during the last quarter. State of Wyoming bought a new position in shares of Arcellx during the 2nd quarter worth about $28,000. Ramirez Asset Management Inc. bought a new stake in shares of Arcellx in the third quarter valued at about $41,000. Finally, PNC Financial Services Group Inc. grew its position in Arcellx by 183.4% during the second quarter. PNC Financial Services Group Inc. now owns 751 shares of the company’s stock worth $49,000 after buying an additional 486 shares in the last quarter. Institutional investors and hedge funds own 96.03% of the company’s stock.

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.